Merck, Tulisokibart, MK-7240, Hidradenitis Suppurativa, HS, Phase 2b Clinical Trial, TL1A, Anti-TL1A Antibody, HiSCR50, HiSCR75

RAHWAY, New Jersey, September 30, 2026 Merck announced positive results from its Phase 2b MK-7240-012 clinical trial evaluating tulisokibart,...